期刊文献+
共找到301篇文章
< 1 2 16 >
每页显示 20 50 100
Effects of cytoreductive surgery combined with hyperthermic perfusion chemotherapy on prognosis of patients with advanced gallbladder cancer
1
作者 Jin-Xiu Wu Rong Hua +2 位作者 Xiang-Ji Luo Feng Xie Li Yao 《World Journal of Gastrointestinal Surgery》 SCIE 2023年第11期2413-2422,共10页
BACKGROUND Gallbladder cancer(GC)is a common malignant tumor and one of the leading causes of cancer-related death worldwide.It is typically highly invasive,difficult to detect in the early stages,and has poor treatme... BACKGROUND Gallbladder cancer(GC)is a common malignant tumor and one of the leading causes of cancer-related death worldwide.It is typically highly invasive,difficult to detect in the early stages,and has poor treatment outcomes,resulting in high mortality rates.The available treatment options for GC are relatively limited.One emerging treatment modality is hyperthermic intraperitoneal chemotherapy(HIPEC).HIPEC involves delivering heated chemotherapy directly into the abdominal cavity.It combines the strategies of surgical tumor resection and localized chemotherapy administration under hyperthermic conditions,aiming to enhance the concentration and effectiveness of drugs within the local tumor site while minimizing systemic toxicity.AIM To determine the effects of cytoreductive surgery(CRS)combined with HIPEC on the short-term prognosis of patients with advanced GC.METHODS Data from 80 patients treated at the Punan Branch of Renji Hospital,Shanghai Jiao Tong University School of Medicine between January 2018 and January 2020 were retrospectively analyzed.The control group comprised 44 patients treated with CRS,and the research group comprised 36 patients treated with CRS combined RESULTS The baseline data of the research and control groups were similar(P>0.05).Six days after surgery,the alanine aminotransferase,aspartate aminotransferase,total bilirubin,and direct bilirubin levels significantly decreased compared to the preoperative levels in both groups(P<0.05).However,the values did not differ between the two groups six days postoperatively(P>0.05).Similarly,the postoperative creatinine and blood urea nitrogen levels were significantly lower than the preoperative levels in both groups(P<0.05),but they did not differ between the groups six days postoperatively(P>0.05).Furthermore,the research group had fewer postoperative adverse reactions than the control group(P=0.027).Finally,a multivariate Cox analysis identified the tumor stage,distant metastasis,and the treatment plan as independent factors affecting prognosis(P<0.05).The three-year survival rate in the study group was higher than that in the control group(P=0.002).CONCLUSION CRS combined with HIPEC lowers the incidence of adverse reactions and improves survival in patients with advanced GC. 展开更多
关键词 Gallbladder diseases chemotherapy cancer regional Perfusion Gallbladder neoplasms PROGNOSIS Regression analysis Survival rate
下载PDF
Application of Regional Arterial Infusion Chemotherapy in Advanced Gastric Cancer 被引量:1
2
作者 Hao Xu Weicheng Wang +4 位作者 Xiaoming Zhang Yi Zhou Jing Zheng Cui Yang Lin Yang 《Journal of Cancer Therapy》 2018年第2期118-129,共12页
Gastric cancer ranks as the fifth most common malignant tumor worldwide and is the third most common cause of cancer-related death. For advanced gastric cancer (AGC), neoadjuvant chemotherapy (NAC) can reduce its stag... Gastric cancer ranks as the fifth most common malignant tumor worldwide and is the third most common cause of cancer-related death. For advanced gastric cancer (AGC), neoadjuvant chemotherapy (NAC) can reduce its stage, increase the rate of radical resection, improve response to treatment, reduce the risk of local recurrence and improve survival rate. Regional arterial infusion chemotherapy (RAIC) is a form of NAC that involves directly injecting chemotherapeutic drugs into the tumor site through the tumor-feeding artery. RAIC increases the local drug concentration around the tumor, thereby improving the therapeutic responses and reducing the adverse effects of the drugs. In recent years, RAIC has attracted increasing attention. This article summarizes the basic principles, procedure, chemotherapy regimens, adverse drug reactions and complications, clinical applications and response evaluation of RAIC in the treatment of AGC. 展开更多
关键词 GASTRIC cancer NEOADJUVANT chemotherapy regional ARTERIAL INFUSION chemotherapy
下载PDF
A Totally Absorbable Multilayer PLGA Implant Device Containing Doxorubicin Inhibited Tumor Growth and Metastasis without Systemic Toxicity in Murine Breast Cancer and an Ideal Pharmacological Paradigm for Regional Chemotherapy
3
作者 Bennett Elzey Sandra Torregrosa-Allen +2 位作者 Peterson Li Ben Ramsey Matthew Shaw 《Journal of Biosciences and Medicines》 2016年第7期66-81,共17页
We hypothesize that a cylinder implant made of multilayer Poly-lactic-co-glycolic-acid (PLGA) membrane can be a method for controlled and extended drug release. We fashioned a multilayer cylindrical implant termed STI... We hypothesize that a cylinder implant made of multilayer Poly-lactic-co-glycolic-acid (PLGA) membrane can be a method for controlled and extended drug release. We fashioned a multilayer cylindrical implant termed STID100 that released doxorubicin for 3 weeks in an orthotopic 4T1 breast cancer model in Balb/C mice. This implant starts as a thin doxorubicin-embedded PLGA membrane, and is then rolled into a cylinder containing an air gap between the membrane layers. Its controlled sustained release delivered 2× the amount of the intravenous (IV) equivalent of doxorubicin, inhibited the primary tumor, and prevented lung metastasis. Importantly it did not cause weight loss, splenomegaly, or cardiac toxicity vs systemically administrated doxorubicin. This favorable safety profile is further substantiated by the finding of no detectable plasma doxorubicin in multiple time points during the 3-week period, and low tumor doxorubicin concentration. The implant system delivered to the specification of an ideal pharmacological paradigm might offer a better coverage of the local tumor, significantly preventing metastatic spread with less drug toxicity to many vital organs, compared to the traditional pharmacology of IV route. The profile of STID made it an attractive therapeutic alternative in metastatic tumor prevention, pain management and many other diverse clinical scenarios. 展开更多
关键词 PLGA DOXORUBICIN IMPLANT Multilayer Membrane METASTASIS Controlled Release Extended Release Polymer Tumor Breast cancer Mice regional chemotherapy Pharmacology
下载PDF
Effect of systemic intravenous chemotherapy combined with regional arterial perfusion chemoembolization on the malignancy of locally advanced gastric cancer
4
作者 Qiang Wang Gang Wu 《Journal of Hainan Medical University》 2017年第14期86-90,共5页
Objective:To study the effect of systemic intravenous chemotherapy combined with regional arterial perfusion chemoembolization on the malignancy of locally advanced gastric cancer. Methods:A total of 90 patients with ... Objective:To study the effect of systemic intravenous chemotherapy combined with regional arterial perfusion chemoembolization on the malignancy of locally advanced gastric cancer. Methods:A total of 90 patients with primary gastric cancer who received treatment in Tianyou Hospital Affiliated to Wuhan University of Science & Technology between January 2014 and May 2016 were collected and divided into control group and observation group according to the random number table method, 45 cases in each group. The control group of patients received routine systemic intravenous chemotherapy + surgical treatment, and the observation group of patients received systemic intravenous chemotherapy combined with local arterial perfusion chemoembolization + surgical treatment. Levels of tumor markers and angiogenesis factors in serum as well as the expression of oncogenes and tumor suppressor genes in gastric cancer tissue were compared between the two groups of patients before and after chemotherapy.Results:Before chemotherapy, the levels of tumor markers and angiogenesis factors in serum as well as the expression of oncogenes and tumor suppressor genes in gastric cancer tissue were not significantly different between the two groups of patients;after chemotherapy, serum CEA, CA724, CA242, AFP, VEGF, Ang-2, COX2 and PD-ECGF levels of observation group were lower than those of control group, andiASPP, p130Cas, ERBB2 and C-myc mRNA expression in gastric cancer tissue were lower than those of control group while GKN1, p16, PTEN, TSPYL5 and merlin mRNA expression in gastric cancer tissue were higher than those of control group.Conclusions: Preoperative systemic intravenous chemotherapy combined with regional arterial perfusion chemoembolization can effectively reduce the malignancy of locally advanced gastric cancer and provide favorable conditions for the operation. 展开更多
关键词 Locally advanced gastric cancer SYSTEMIC intravenous chemotherapy regional ARTERIAL PERFUSION CHEMOEMBOLIZATION Tumor markers ONCOGENE
下载PDF
Regional but fatal: Intraperitoneal metastasis in gastric cancer 被引量:8
5
作者 Jia Wei Nan-Die Wu Bao-Rui Liu 《World Journal of Gastroenterology》 SCIE CAS 2016年第33期7478-7485,共8页
Peritoneal carcinomatosis appears to be the most common pattern of metastasis or recurrence and is associated with poor prognosis in gastric cancer patients. Many efforts have been made to improve the survival in pati... Peritoneal carcinomatosis appears to be the most common pattern of metastasis or recurrence and is associated with poor prognosis in gastric cancer patients. Many efforts have been made to improve the survival in patients with peritoneal metastasis. Hyperthermic intraperitoneal chemotherapy remains a widely accepted strategy in the treatment of peritoneal dissemination. Several phase Ⅱ-Ⅲ studies confirmed that the combined cytoreducitve surgery and hyperthermic intraperitoneal chemotherapy resulted in longer survival in patients with peritoneal carcinomatosis. In addition,proper selection and effective regional treatment in patients with high risk of peritoneal recurrence after resection will further improve prognosis in local advanced gastric cancer patients. 展开更多
关键词 GASTRIC cancer INTRAPERITONEAL METASTASIS regional METASTASIS Cytoreductive surgery Hyperthermic INTRAPERITONEAL chemotherapy
下载PDF
Comparison of regional arterial chemotherapy and systemic intravenous chemotherapy for advanced pancreatic cancer:a systematic review and meta-analysis
6
作者 Chengqing Li Wenyi Guo +3 位作者 Shihong Chen Jianwei Xu Feng Li Lei Wang 《Journal of Pancreatology》 2022年第2期49-57,共9页
Chemotherapy is the mainstay of treatment for advanced pancreatic cancer(stageⅢ/Ⅳ).However,conventional systemic intravenous chemotherapy(SIC)has been unsatisfactory for pancreatic cancer.In recent years,regional ar... Chemotherapy is the mainstay of treatment for advanced pancreatic cancer(stageⅢ/Ⅳ).However,conventional systemic intravenous chemotherapy(SIC)has been unsatisfactory for pancreatic cancer.In recent years,regional arterial infusion chemotherapy(RAIC)has been clinically used as a new chemotherapy regimen for the treatment of advanced pancreatic cancer,but its efficacy is controversial.The purpose of this study was to evaluate the clinical efficacy and safety of RAIC.We searched literatures in databases such as PubMed,EMBASE,Cochrane Library,Web of Science,and CNKI.After screening,this meta-analysis finally included 9 randomized controlled trials(RCTs)with 444 patients(230 RAIC and 214 SIC).We used the Cochrane Risk of Bias 2.0 tool to assess risk of bias for included RCTs.Outcomes were overall survival(OS),overall response rate(ORR),adverse events rate(AER),and pain remission rate.Outcome indicators used relative risk(RR)and its 95%confidence interval(CI)as effect analysis statistics.The results showed that RAIC had some advantages over SIC in terms of ORR,OS,incidence of leukopenia,and pain remission.In conclusion,compared with SIC,RAIC has better clinical efficacy and lower toxicity in the treatment of advanced pancreatic cancer. 展开更多
关键词 Advanced pancreatic cancer Adverse events rate Clinical efficacy META-ANALYSIS regional arterial infusion chemo-therapy Systemic intravenous chemotherapy
原文传递
Conversion of Unresectable to Resectable Liver Metastases from Colorectal Carcinoma Using Hepatic Arterial Chronomodulated Chemotherapy: A Case Report and Short Literature Review
7
作者 Evgeny Y. Parnes Maria S. Sayapina +5 位作者 Alexey A. Tryakin Mohamed Bouchahda Pasquale F. Innominato Jean-Francois Morere Francis A. Levi Rene Adam 《Surgical Science》 2018年第10期358-366,共9页
Background: The regional chronomodulated hepatic arterial infusion chemotherapy (HAIC) is an effective regimen for the treatment of patients with unresectable liver metastases from colorectal cancer, especially for th... Background: The regional chronomodulated hepatic arterial infusion chemotherapy (HAIC) is an effective regimen for the treatment of patients with unresectable liver metastases from colorectal cancer, especially for the conversion into resectability. Aim: To demonstrate that chronomodulated HAI triplet chemotherapy according to OPTILIV protocol is well tolerated and displayed high antitumor activity in this heavily-pretreated patient. Case Presentation: A 54 years old patient from Russia was treated for a tumor in the ascending colon presented with 13 hepatic metastases ranging from 0.3 to 2.7 cm in diameter. He underwent a laparoscopic right hemicolectomy, 12 cycles of FOLFIRINOX combined to bevacizumab for the last 5 cycles, resulting in a partial response according to CT scan. It was decided to perform a two-stage hepatectomy at Paul Brousse hospital: left partial hepatectomy allowed the excision of 9 lesions. Radio frequency ablation was performed in 2 nodular lesions. Afterwards, the patient received 5 cycles of chronomodulated triplet chemotherapy into the hepatic artery, according to the OPTILIV protocol design, yet without cetuximab, because of the KRAS mutation in the liver metastases, with a partial re-sponse. The patient could then undergo the second stage of the planned right hepatectomy, which turned out to be an R0 resection followed by receiving three courses of chronomodulated HAIC. Disease progression was documented after 3 months. Chronomodulated FOLFIRI chemotherapy was re-started intravenously, in combination with Aflibercept and it was associated with further disease progression. The genetic analysis of our patient’s cancer revealed a high level of MSI. The patient was included in the Phase 2 CheckMate-142 trial and received nivolumab 3 mg/kg every 2 weeks within 3 months. Treatment was discontinued due to ineffectiveness. Then the patient underwent radiotherapy geared towards reduction of pain. Afterwards, the patient died from the disease progression 2 years after the beginning of treatment. Conclusion: In this article, the authors report a clinical case with chronomodulated HAIC as rescue therapy in a heavily pretreated patient with metastatic colorectal cancer, allowing to achieve an objective response despite prior progression on FOLFIRINOX (the same triplet chemo by IV route). This strategy permitted to overcome drug resistance and to perform further complete resection of the liver me-tastases with prolonged patient survival. Thus, chronomodulated HAI is useful in patients with liver metastases from colorectal cancer and de-serves to be further assessed prospectively in clinical trials chemotherapy. 展开更多
关键词 The regional Chronomodulated HEPATIC ARTERIAL Infusion chemotherapy Metastatic Colorectal cancer CONVERSION of UNRESECTABLE to Resectable Liver METASTASES
下载PDF
Performance of the Multiprofessional Team in Cytoreductive Surgeries with Intraperitoneal Hyperthermic Chemotherapy:Experience Reporting
8
作者 Cecília da Silva Angelo(RN) Ademar Lopes(PhD) +8 位作者 Catharina Ferreira de Meira Pachioni(MSc) Eduardo Henrique Giroud Joaquim(MSc) Samuel Aguiar Junior(PhD) Gustavo Cardoso Guimaraes(PhD) Glauco Baiocchi Neto(PhD) Felipe JoséFernandez Coimbra(PhD) Isabel Miranda Bonfim(MSc) Rita de Cassia Burgos de Oliveira(PhD) Tailine Ligia Tadini(RN) 《Journal of Pharmacy and Pharmacology》 2018年第11期965-969,共5页
Purpose:This study aims at reporting the experience of a cancer hospital’s multiprofessional team with surgery patients in performing cytoreductive surgeries associated with hyperthermic intraperitoneal chemotherapy.... Purpose:This study aims at reporting the experience of a cancer hospital’s multiprofessional team with surgery patients in performing cytoreductive surgeries associated with hyperthermic intraperitoneal chemotherapy.Methods:It is a reporting about the experience of the multiprofessional team at AC Camargo Cancer Center’s surgery center,which operates in cytoreductive surgeries with hyperthermic intraperitoneal chemotherapy,thus guaranteeing the surgery patient’s safety.Results:No safety report for the surgery patient subjected to intraperitoneal hypothermic chemotherapy was found in the literature.Therefore,the surgery center’s multiprofessional team’s practice was based on standards for manipulating chemotherapeutic agents and for safely administering medication.A checklist was elaborated for cytoreductive surgeries with hyperthermic intraperitoneal chemotherapy based on the surgery patient safety protocol and the institution’s multiprofessional team’s experience.Conclusions:From the multiprofessional team’s experiences in cytoreductive surgeries with hyperthermic intraperitoneal chemotherapy,the importance of elaborating a checklist to promote the quality of assistance and guarantee patient safety during the entire intraoperative phase became evident. 展开更多
关键词 Patient safety chemotherapy for cancer by regional PERFUSION CHECKLIST
下载PDF
肝动脉灌注化疗联合仑伐替尼治疗巴塞罗那临床肝癌B或C期肝细胞癌
9
作者 于海东 郭应兴 +3 位作者 雷振武 杨海明 孙世蒙 马存凯 《中国介入影像与治疗学》 北大核心 2024年第2期70-74,共5页
目的观察肝动脉灌注化疗(HAIC)联合仑伐替尼治疗巴塞罗那临床肝癌(BCLC)B或C期肝细胞癌(HCC)效果,分析影响患者生存时间的因素。方法 回顾性分析104例BCLC B或C期HCC患者资料,根据治疗方案将其归入观察组(46例,接受HAIC联合仑伐替尼治疗... 目的观察肝动脉灌注化疗(HAIC)联合仑伐替尼治疗巴塞罗那临床肝癌(BCLC)B或C期肝细胞癌(HCC)效果,分析影响患者生存时间的因素。方法 回顾性分析104例BCLC B或C期HCC患者资料,根据治疗方案将其归入观察组(46例,接受HAIC联合仑伐替尼治疗)及对照组(58例,仅接受HAIC);比较2组疗效、不良反应及患者总生存期(OS)和无进展生存期(PFS),以Cox回归分析评估OS影响因素。结果 治疗后3、6个月,观察组改良实体瘤疗效评价标准(mRECIST)评估结果均优于对照组(P均<0.05);治疗后1年,组间mRECIST评估结果差异无统计学意义(P>0.05)。观察组患者总生存率高于对照组(P<0.05),而组间无进展生存率差异无统计学意义(P>0.05)。观察组皮疹发生率高于对照组(P<0.05)。多因素Cox回归分析结果显示,相比单一HAIC,HAIC联合仑伐替尼[风险比(HR)=0.425,95%CI(0.255,0.791)]可延长患者OS;相比治疗前美国东部肿瘤协作组(ECOG)评分1、AFP≥400μg/ml、瘤灶数目≥3及BCLC C期,治疗前ECOG评分0、AFP<400μg/ml、瘤灶数目≤2及BCLC B期均为HCC患者OS独立保护因素(P均<0.05)。结论 HAIC联合仑伐替尼治疗BCLC B期或C期HCC安全、有效;治疗前ECOG评分、血清AFP水平、瘤灶数目及BCLC分期均为OS影响因素。 展开更多
关键词 肝细胞 化学疗法 癌症 局部灌注 预后
下载PDF
肝动脉灌注化疗栓塞术联合信迪利单抗治疗晚期原发性肝癌近期疗效及远期生存率
10
作者 覃雪 丁莉 蒋蜀梅 《安徽医药》 CAS 2024年第2期390-395,共6页
目的 探讨肝动脉灌注化疗栓塞术(TACE)联合信迪利单抗治疗晚期原发性肝癌(PLC)的近期疗效及远期生存率。方法2018年4月至2019年4月在资阳市人民医院82个随机双盲实验中,对符合AASLD指南,巴塞罗那(BCLC)分期为B/C期者;肝功能Child-Pugh分... 目的 探讨肝动脉灌注化疗栓塞术(TACE)联合信迪利单抗治疗晚期原发性肝癌(PLC)的近期疗效及远期生存率。方法2018年4月至2019年4月在资阳市人民医院82个随机双盲实验中,对符合AASLD指南,巴塞罗那(BCLC)分期为B/C期者;肝功能Child-Pugh分级A/B级的PLC进行研究。经计算机生成的随机列表随机分配,对照组仅行TACE治疗,研究组则采用TACE联合信迪利单抗治疗,连续治疗4周期比较两组临床疗效、肿瘤标志物水平T淋巴细胞亚群指标变化,随访观察远期生存情况。结果 对照组和研究组病人各41例,治疗后1个月时对照组肿瘤控制率(DCR)为80.49%,研究组DCR为92.68%,组间差异无统计学意义(χ^(2)=2.63,P=0.105);治疗后3个月时研究组DCR为87.80%,明显高于对照组的73.17%,组间差异有统计学意义(χ^(2)=4.00,P=0.046)。治疗前,研究组甲胎蛋白(AFP)、高尔基体蛋白73(GP-73)及甲胎蛋白异质体3(AFP-L3)水平分别为(82.74±5.77)μg/L、(90.27±4.67)μg/L及(148.74±62.15)mg/L,对照组3项指标水平依次为(84.28±6.02)μg/L、(89.74±5.32)μg/L、(156.20±41.03)mg/L,组间数据差异无统计学意义(t=1.18,t=0.48,t=0.64,P>0.05);治疗后研究组AFP、GP-73及AFP-L水平分别为(14.22±2.60)μg/L、(49.39±5.63)μg/L、(82.41±21.75)mg/L,均显著低于对照组的(57.13±6.21)μg/L、(65.28±3.74)μg/L、(117.20±35.62)mg/L,组间差异有统计学意义(t=40.81,t=15.05,t=5.34,P<0.05)。治疗前,研究组CD4+、CD8+及CD4+/CD8+水平分别为(29.17±6.33)%、(27.86±3.92)%、(1.04±0.25),对照组依次为(28.63±5.41)%、(28.53±4.63)%及(1.01±0.20),组间差异无统计学意义(t=0.42,t=0.73,t=0.60,P>0.05);治疗后研究组CD4+、CD4+/CD8+水平分别为(36.28±4.11)%、(1.33±0.40),显著高于对照组的(30.52±5.01)%及(1.09±0.32),组间差异有统计学意义(t=5.69,t=3.00,P<0.05)。治疗前,研究组CD151、CD168、CD9及CD63分别为(94.18±18.33)%、(96.27±16.08)%、(98.52±16.33)%、(94.57±10.96)%,对照组4项数据水平依次为(96.31±21.05)%、(97.24±14.20)%、(99.36±17.41)%、(93.64±12.60)%,组间差异无统计学意义(t=0.49,t=0.29,t=0.23,t=0.36,P>0.05);治疗后研究组CD151、CD168指标水平分别为(32.06±6.34)%、(31.28±4.78)%,显著低于对照组的(87.36±15.03)%、(76.34±11.52)%,而CD9及CD63水平分别为(210.54±27.12)%、(247.02±30.21)%,显著高于对照组的(104.52±12.94)%、(110.32±16.30)%,组间差异有统计学意义(t=21.71,t=23.13,t=22.59,t=25.50,P<0.05)。治疗后随访36~48个月,研究组失访3例,总生存率为47.37%,对照组失访1例,总生存率为25.0%,组间差异有统计学意义(χ^(2)=4.24,P=0.040)。研究组≥3级毒副反应总发生率为13.16%,与对照组27.5%差异无统计学意义(χ^(2)=2.46,P=0.117)。结论 TACE联合PD-1治疗晚期PLC可降低机体肿瘤标志物水平、提升病人的免疫功能及近期疗效,同时可延长病人远期生存率,严重毒副反应发生率较低。 展开更多
关键词 原发性肝癌 化学疗法 肿瘤 局部灌注 肝动脉热灌注化疗栓塞 信迪利单抗 疗效 生存率
下载PDF
基于炎症营养参数的评分系统预测胃上部癌新辅助化疗效果的研究 被引量:1
11
作者 朱红苹 刘睿清 +3 位作者 张宪祥 张茂申 王东升 卢云 《精准医学杂志》 2023年第5期427-430,435,共5页
目的探讨局部进展期胃上部癌患者新辅助化疗(NACT)前后炎症营养指标与NACT疗效的关系,并建立临床预测模型。方法选取2013年4月—2022年1月于我院胃肠外科接受NACT的胃上部癌患者117例,根据化疗结果分为有效组与无效组,收集患者的年龄、... 目的探讨局部进展期胃上部癌患者新辅助化疗(NACT)前后炎症营养指标与NACT疗效的关系,并建立临床预测模型。方法选取2013年4月—2022年1月于我院胃肠外科接受NACT的胃上部癌患者117例,根据化疗结果分为有效组与无效组,收集患者的年龄、性别、吸烟史、饮酒史、首发症状、肿瘤部位、肿瘤分化程度、肿瘤临床分期、肿瘤病理类型、NACT前1周内及NACT后1周内的血常规结果等临床资料,经单因素及多因素分析后筛选出影响NACT疗效的因素,进一步构建列线图模型并验证该模型的性能。结果多因素分析结果显示,患者NACT前后的血浆中性粒细胞与淋巴细胞比值(NLR)差值(△NLR)(OR=2.043,95%CI=1.334~3.127,P<0.05)、血浆血小板与淋巴细胞比值(PLR)差值(△PLR)(OR=1.007,95%CI=1.000~1.014,P<0.05)、血清白蛋白(Alb)差值(△Alb)(OR=0.936,95%CI=0.878~0.997,P<0.05)以及T分期(OR=4.044,95%CI=1.128~14.501,P<0.05)均为影响NACT疗效的独立危险因素。基于多因素分析结果构建胃上部癌NACT疗效列线图预测模型,该模型受试者特征曲线下面积为0.877,绘制的校准曲线及临床决策曲线显示校准度较好且与实际结果较一致。结论胃上部癌患者△NLR、△PLR、△Alb及T分期为影响NACT疗效的独立危险因素,胃上部癌NACT疗效预测模型具有良好的预测性能和临床应用价值。 展开更多
关键词 胃肿瘤 慢性病指标 营养评价 化学疗法 肿瘤 局部灌注 危险因素 回归分析
下载PDF
乳腺癌化疗脑局部一致性异常的静息态fMRI研究
12
作者 周文苏 李瑗 +5 位作者 夏建国 张继 田为中 姚天琦 朱正才 焦良和 《中国CT和MRI杂志》 2023年第9期4-6,18,共4页
目的通过局部一致性(ReHO)来探讨乳腺癌患者化疗后长期认知功能水平及其与神经心理学量表和血液生化指标的相关性。方法选取29名化疗后的乳腺癌患者(C+)和28名未经化疗的同龄乳腺癌患者(C-)进行静息态功能磁共振检查、神经心理学量表测... 目的通过局部一致性(ReHO)来探讨乳腺癌患者化疗后长期认知功能水平及其与神经心理学量表和血液生化指标的相关性。方法选取29名化疗后的乳腺癌患者(C+)和28名未经化疗的同龄乳腺癌患者(C-)进行静息态功能磁共振检查、神经心理学量表测试和血液学检查。结果与C-组相比,C+组运动疲劳、认知疲劳、感知认知障碍、他人的评价、对生活质量的影响评分得分增高,感知认知能力得分降低,差异有统计学意义(P<0.05),提示C+组认知能力下降。C+组左内侧和旁扣带回SmReHO值降低,左侧颞极:颞中回、右侧颞上回、左侧中央后回、右侧补充运动区SmReHO值升高(体素水平FWE校正,P<0.01)。相关性分析显示C+组右侧颞上回SmReHO值与数字符号实验、对生活质量的影响评分呈正相关,左内侧和旁扣带回SmReHO值与感知认知能力呈负相关,右侧补充运动区、左侧中央后回SmReHO值与胆固醇水平呈负相关。结论乳腺癌化疗患者长期存在认知功能损伤和脑功能活动异常,ReHO改变可能是其病理基础。 展开更多
关键词 乳腺癌 化疗 认知功能 局部一致性 静息态功能磁共振
下载PDF
膀胱癌术后患者经济毒性水平多中心调查及其机制研究
13
作者 程文瑜 高凯霞 +3 位作者 王静 赵琪 张卜升 高俊平 《军事护理》 CSCD 北大核心 2023年第12期42-45,共4页
目的了解膀胱灌注化疗患者经济毒性现况并分析原因,为制订干预措施提供参考依据。方法便利抽样法选取太原市3所三级甲等医院泌尿外科418例行膀胱癌术后灌注化疗患者为调查对象,采用一般资料调查表、癌症患者报告结局的经济毒性评分量表... 目的了解膀胱灌注化疗患者经济毒性现况并分析原因,为制订干预措施提供参考依据。方法便利抽样法选取太原市3所三级甲等医院泌尿外科418例行膀胱癌术后灌注化疗患者为调查对象,采用一般资料调查表、癌症患者报告结局的经济毒性评分量表、心理弹性量表、领悟社会支持量表对其进行调查并分析经济毒性的影响因素。结果膀胱灌注化疗患者经济毒性得分为20.00(18.5,23.5)分;多元线性回归分析显示,患者年龄、家庭收入、受教育程度、医保类型、心理弹性和社会支持度是主要影响因素(均P<0.01)。结论膀胱灌注化疗患者普遍存在经济毒性,且影响因素较多,医护人员应早期识别其经济毒性、制订个体化干预措施、运用“优势视角”理论增强患者应对疾病的信心,提升其心理弹性水平并充分利用社会支持资源以降低患者的经济毒性水平。 展开更多
关键词 膀胱癌 灌注化疗 经济毒性 心理弹性 社会支持 护理
下载PDF
ANA-12靶向抑制BDNF/TrkB信号缓解奥沙利铂诱导化疗大鼠的痛觉行为
14
作者 赵佳佳 万文军 +2 位作者 杨荷雨 谢敏 刘玲 《天津医药》 CAS 北大核心 2023年第1期35-40,共6页
目的 探讨ANA-12靶向抑制脑源性神经营养因子(BDNF)/酪氨酸激酶受体B(TrkB)信号缓解奥沙利铂(OXA)化疗痛的作用及机制。方法 将18只雄性SD大鼠按照随机数字表法分为3组:对照组、OXA组以及OXA+ANA-12组,每组6只。OXA组和OXA+ANA-12组腹... 目的 探讨ANA-12靶向抑制脑源性神经营养因子(BDNF)/酪氨酸激酶受体B(TrkB)信号缓解奥沙利铂(OXA)化疗痛的作用及机制。方法 将18只雄性SD大鼠按照随机数字表法分为3组:对照组、OXA组以及OXA+ANA-12组,每组6只。OXA组和OXA+ANA-12组腹腔注射OXA(4 mg/kg,连续5 d)构建化疗痛模型,模型构建成功后OXA+ANA-12组进行ANA-12鞘内给药(20 g/L)。给药完毕后,对各组大鼠进行痛觉行为学检测,记录大鼠自发性缩足反射次数和机械痛觉阈值的变化;采用HE染色、免疫印记和免疫荧光检测脊髓炎性细胞浸润情况及白细胞介素(IL)-1β、肿瘤坏死因子(TNF)-α、离子钙结合衔接分子1(Iba1)、BDNF、TrkB和核转录因子κB(NF-κB)表达水平变化。结果 行为学分析显示,与对照组相比,OXA连续注射可显著增加自发缩足次数以及机械刺激敏感性;与OXA组相比,鞘内注射ANA-12显著降低自发缩足次数,增加机械性痛觉阈值。形态学及蛋白表达分析显示,与对照组相比,OXA诱导脊髓炎症,激活BDNF/TrkB信号,上调IL-1β、TNF-α、Iba1和NF-κB的表达;与OXA组相比,ANA-12显著抑制BDNF/TrkB信号,下调IL-1β、TNF-α、Iba1和NF-κB的表达水平。结论 ANA-12鞘内给药通过阻断BDNF/TrkB信号来抑制脊髓炎症,缓解化疗痛。 展开更多
关键词 化学疗法 肿瘤 局部灌注 脊髓炎 小神经胶质细胞 脑源性神经营养因子 受体 trkB 奥沙利铂 ANA-12
下载PDF
微波深部热疗联合区域灌注化疗治疗晚期胰腺癌的临床研究
15
作者 梁宗志 庞俊芳 +3 位作者 黄亚鹏 李斌 胡胜男 张慧珍 《当代医学》 2023年第14期43-46,共4页
目的研究微波深部热疗联合区域灌注化疗治疗晚期胰腺癌的临床疗效。方法选取2016年1月至2017年1月本院治疗的90例晚期胰腺癌患者作为研究对象,随机分为观察组与对照组,每组45例。对组组采用区域灌注化疗,观察组采用微波深部热疗联合区... 目的研究微波深部热疗联合区域灌注化疗治疗晚期胰腺癌的临床疗效。方法选取2016年1月至2017年1月本院治疗的90例晚期胰腺癌患者作为研究对象,随机分为观察组与对照组,每组45例。对组组采用区域灌注化疗,观察组采用微波深部热疗联合区域灌注化疗,比较两组临床疗效、临床症状缓解率、卡诺夫斯凯计分(KPS)评分提升>15分占比、生存率及不良反应发生率。结果观察组治疗总有效率为75.56%,高于对照组的37.78%,差异有统计学意义(P<0.05)。观察组黄疸、腹水、腹痛腹胀缓解率及KPS评分提升>15分占比均高于对照组,差异有统计学意义(P<0.05)。观察组治疗后6、12、18个月的生存率均高于对照组,差异有统计学意义(P<0.05);两组治疗后2、3、5年生存率比较差异无统计学意义。两组不良反应发生率比较差异无统计学意义。结论微波深部热疗联合区域灌注化疗治疗晚期胰腺癌临床疗效显著,可有效改善患者临床症状,延长生存期,且无严重不良反应,值得临床推广应用。 展开更多
关键词 微波深部热疗 区域灌注化疗 晚期胰腺癌
下载PDF
吡柔比星与吉西他滨膀胱热灌注化疗对浅表性膀胱癌手术患者的疗效比较
16
作者 孙青风 仇晓宇 田龙江 《转化医学杂志》 2023年第3期157-161,172,共6页
目的探究吡柔比星与吉西他滨膀胱热灌注化疗对浅表性膀胱癌手术患者的疗效及对血清肿瘤标志物水平的影响。方法选取2017年7月—2021年7月收治的114例浅表性膀胱癌为研究对象,按照治疗方式不同分为对照组和研究组,每组57例。2组均手术治... 目的探究吡柔比星与吉西他滨膀胱热灌注化疗对浅表性膀胱癌手术患者的疗效及对血清肿瘤标志物水平的影响。方法选取2017年7月—2021年7月收治的114例浅表性膀胱癌为研究对象,按照治疗方式不同分为对照组和研究组,每组57例。2组均手术治疗,对照组采用吡柔比星膀胱热灌注化疗辅助,研究组采用吉西他滨膀胱热灌注化疗辅助,观察并对比近期治疗效果、血清肿瘤标志物[可溶性细胞间黏附分子-1(sICAM-1)、成纤维细胞生长因子(FGF)、血管内皮生长因子(VEGF)、癌胚抗原(CEA)]水平、安全性及生存指标[无进展生存期(PFS)、总生存期(OS)]。结果治疗后,研究组总有效率为80.70%(46/57)和疾病控制率为89.47%(51/57)均高于对照组[63.16%(36/57)和66.67%(38/57)](P<0.05)。治疗后,2组血清sICAM-1、FGF、VEGF、CEA水平较治疗前均降低,且研究组低于对照组(P<0.05)。研究组不良反应发生率为8.77%(5/57)和复发率为8.77%(5/57)低于对照组[24.56%(14/57)和29.82%(17/57)](P<0.05)。研究组PFS、OS均长于对照组(P<0.05)。结论浅表性膀胱癌手术患者术后采用吉西他滨膀胱热灌注化疗效果明显,能显著降低sICAM-1、FGF、VEGF、CEA水平,延长生存时间,且有较高安全性。 展开更多
关键词 膀胱肿瘤 浅表性膀胱癌 吡柔比星 吉西他滨 化学疗法 肿瘤 局部灌注 血管内皮生长因子 癌胚抗原 总生存期
下载PDF
青中年高级别B细胞淋巴瘤患者27例临床分析
17
作者 王媛 吕桂阳 +1 位作者 赵鹏 王玲 《精准医学杂志》 2023年第6期481-484,共4页
目的分析青中年高级别B细胞淋巴瘤(HGBL)患者的临床特征、治疗效果与预后。方法回顾性分析27例青中年HGBL患者的临床资料。结果在27例青中年HGBL患者中,相较于HGBL非特指型(HGBL-NOS)患者,Ann Arbor分期晚、aaIPI评分高、结外受侵器官... 目的分析青中年高级别B细胞淋巴瘤(HGBL)患者的临床特征、治疗效果与预后。方法回顾性分析27例青中年HGBL患者的临床资料。结果在27例青中年HGBL患者中,相较于HGBL非特指型(HGBL-NOS)患者,Ann Arbor分期晚、aaIPI评分高、结外受侵器官多、骨髓累及在双重/三重打击淋巴瘤(HGBL-DT)患者中更常见,差异具有统计学意义(P<0.05)。在近期疗效对比中,HGBL-NOS患者的总有效率优于HGBL-DT患者,差异具有统计学意义(P<0.05)。在远期疗效对比中,HGBL-NOS患者的疾病无进展生存期与总生存期均优于HGBL-DT患者,差异具有统计学意义(P<0.05)。在6例早期HGBL-NOS患者中,接受R-CHOP/EPOCH方案的治疗者3例,接受高强度化疗方案的治疗者3例,其疗效均达到缓解。在9例晚期HGBL-NOS患者中,接受R-CHOP/EPOCH方案的治疗者8例,其中5例疗效达到缓解;接受高强度化疗方案的治疗者1例,该患者疗效达到CR。结论在青中年患者中,HGBL-DT较HGBL-NOS侵袭性更强、预后更差,HGBL-DT患者可以考虑行高强度化疗方案治疗。 展开更多
关键词 淋巴瘤 B细胞 化学疗法 肿瘤 局部灌注 无进展生存期 疗效比较研究 预后
下载PDF
进展期胃癌术后奥沙利铂早期循环式腹腔热灌注化疗联合全身化疗的临床观察 被引量:21
18
作者 崔海滨 葛怀娥 +2 位作者 白希永 臧春霞 张媛媛 《中国全科医学》 CAS CSCD 北大核心 2013年第23期2740-2742,共3页
目的观察进展期胃癌术后奥沙利铂早期循环式腹腔热灌注化疗联合全身化疗的临床疗效。方法选择2006年3月—2009年3月我院收治的可根治性切除的进展期胃癌患者86例,采用随机数字表法将患者随机分为两组:对照组43例和治疗组43例。对照组患... 目的观察进展期胃癌术后奥沙利铂早期循环式腹腔热灌注化疗联合全身化疗的临床疗效。方法选择2006年3月—2009年3月我院收治的可根治性切除的进展期胃癌患者86例,采用随机数字表法将患者随机分为两组:对照组43例和治疗组43例。对照组患者胃癌术后2~3周行全身化疗。治疗组患者根据胃癌术后恢复状况第1~2天开始行循环式腹腔热灌注化疗,1次/d,90 min/次,连续4 d,术后1个月行全身化疗。观察两组毒副作用及并发症,术后2年复发率及术后1、3年生存率。结果两组患者均无手术死亡。两组患者Ⅰ~Ⅱ度骨髓抑制、Ⅲ~Ⅳ度骨髓抑制、Ⅰ~Ⅱ度恶心呕吐、Ⅲ~Ⅳ度恶心呕吐、切口感染、吻合口漏、粘连性肠梗阻发生率比较,差异均无统计学意义(P>0.05)。治疗组43例患者胃癌术后早期腹腔热灌注化疗均顺利完成,术后1年时失访1例,对照组患者2年内复发率〔27.9%(12/43)〕较治疗组〔7.1%(3/42)〕升高、术后3年生存率〔37.2%(16/43)〕较治疗组〔73.8%(31/42)〕降低,差异均有统计学意义(P<0.05);两组术后1年生存率〔90.7%(39/43)与95.2%(40/42)〕比较,差异无统计学意义(P>0.05)。结论进展期胃癌术后早期循环式腹腔热灌注化疗联合全身化疗可明显降低腹腔复发率,无明显毒副作用,不增加术后并发症的发生率,能提高患者中远期生存率。 展开更多
关键词 胃肿瘤 奥沙利铂 化学疗法 肿瘤 局部灌注 抗肿瘤联合化疗方案
下载PDF
恩度肝动脉灌注联合肝动脉化疗栓塞治疗中晚期原发性肝癌的生存分析 被引量:30
19
作者 刘琪 武振明 +1 位作者 齐秀恒 郭茜 《临床肝胆病杂志》 CAS 2015年第2期225-227,共3页
目的探讨恩度肝动脉灌注联合经导管肝动脉化疗栓塞治疗中晚期肝癌的疗效。方法选取2009年9月-2011年6月天津医科大学附属石油医院收治的76例中晚期肝癌患者。其中44例给予恩度肝动脉灌注联合经导管肝动脉化疗栓塞治疗,其余32例作为对照... 目的探讨恩度肝动脉灌注联合经导管肝动脉化疗栓塞治疗中晚期肝癌的疗效。方法选取2009年9月-2011年6月天津医科大学附属石油医院收治的76例中晚期肝癌患者。其中44例给予恩度肝动脉灌注联合经导管肝动脉化疗栓塞治疗,其余32例作为对照组,仅行经导管肝动脉化疗栓塞治疗。治疗后,所有患者不定期行CT或磁共振成像(MRI)检查,观察肿瘤复发或转移情况以及有无肿瘤新生血管形成。计数资料组间比较采用χ2检验,Kaplan-Meier法绘制生存曲线,Log-rank法分析两组术后生存差异。结果恩度治疗组的治疗有效率(RR)高于对照组(70.45%vs 43.75%),差异有统计学意义(χ2=5.47,P<0.05);疾病控制率(DCR)高于对照组(84.09%vs 56.25%),差异有统计学意义(χ2=7.18,P<0.01);两组中位无进展生存时间(m PFS)分别为9.00个月和5.00个月,差异有统计学意义(P=0.044)。中位生存期(m OS)分别为10.64个月和8.11个月,差异无统计学意义(P=0.448)。结论采用恩度肝动脉灌注联合经导管肝动脉化疗栓塞治疗中晚期肝癌,可明显改善患者近期疗效及PFS,但对总生存期的改善不明显。 展开更多
关键词 肝肿瘤 内皮抑素类 化学疗法 肿瘤 局部灌注 化学栓塞 治疗性
下载PDF
选择性区域灌注化疗对胃癌根治术后患者预后的影响 被引量:7
20
作者 吴有军 何建苗 +4 位作者 杨波 秦荣 曹志宇 董立国 蒲永东 《解放军医学杂志》 CAS CSCD 北大核心 2011年第11期1211-1213,共3页
目的评价选择性区域灌注化疗对根治性胃癌切除术后患者预后的影响。方法 2003年1月-2005年12月解放军309医院普外科收治的胃癌患者共127例,入院后完善辅助检查除外远处转移,随机分为术中置泵(置泵组)和术中不置泵(对照组)两组。置泵组... 目的评价选择性区域灌注化疗对根治性胃癌切除术后患者预后的影响。方法 2003年1月-2005年12月解放军309医院普外科收治的胃癌患者共127例,入院后完善辅助检查除外远处转移,随机分为术中置泵(置泵组)和术中不置泵(对照组)两组。置泵组共63例,其中男51例,女12例,年龄50.7±6.2岁;对照组共64例,其中男54例,女10例,年龄53.3±7.5岁。两组在性别、年龄、TNM分期、病变部位、病理类型等方面的构成无统计学差异(P>0.05)。所有患者均行胃癌根治术,置泵组术中放置胃网膜右动、静脉和腹腔化疗泵,术后全身化疗联合区域灌注化疗,对照组术后仅行静脉化疗。比较两组并发症、局部复发率、肝脏转移率、腹腔转移率、1年生存率、3年生存率、5年生存率等指标。结果所有患者均成功实施手术,手术并发症主要为胃瘫和切口感染,多数患者完成6周期术后化疗,主要不良反应为轻到中度的恶心呕吐和白细胞减少,无手术和化疗相关死亡。置泵组和对照组分别有6例和9例患者未能完成化疗,原因包括不能耐受及化疗泵堵塞等。置泵组随访11.7~60个月,失访2例,对照组随访10.5~60个月,失访4例。置泵组和对照组间比较,局部复发率(17.5%,32.8%),肝脏转移率(27.0%,43.8%),腹腔转移率(14.3%,29.7%),3年生存率(71.4%,53.1%)和5年生存率的差异均有统计学意义(46.0%,28.1%,P均<0.05),但1年生存率间差异无统计学意义(92.1%,87.5%,P>0.05)。结论胃癌根治术后的选择性区域灌注化疗是对现有治疗模式的一种有益补充,值得临床推广应用。 展开更多
关键词 胃肿瘤 胃切除术 根治性 化学疗法 肿瘤 局部灌注 化疗泵
下载PDF
上一页 1 2 16 下一页 到第
使用帮助 返回顶部